Hartmut Ehrlich Abivax's guest appearances

Hartmut Ehrlich Abivax

Empowered Patient Podcast

Mark Allen

David Katz

Rosalind Picard

David Solomon

Matt Murphy

Robin Smith

Thomas Cowan

Greg Miller

Travis Mickle

Justin Miller

Sean Tucker

Matt Wilson

Chris Young

Jim Martin

Robin Zander

OwlTail

Hartmut Ehrlich

Dr. Hartmut Ehrlich, CEO, Abivax  gives an update of the French biotech's phase-2b clinical trial drug candidate ABX464 which has shown impressive results.  Dr. Ehrlich discusses how this revolutionary small molecule for oral administration has shown strong anti-inflammatory effects to solve the unmet needs of patients with inflammatory conditions like ulcerative colitis, Crohn's disease, and arthritis by using the body's own immune system to fight the diseases. @abivax #abivax  #inflammation #IBD #rheum Abivax.com Download the transcript here

Dr. Hartmut Ehrlich, CEO, Abivax  gives an update of the French biotech's phase-2b clinical trial drug candidate ABX464 which has shown impressive results.  Dr. Ehrlich discusses how this revolutionary small molecule for oral administration has shown strong anti-inflammatory effects to solve the unmet needs of patients with inflammatory conditions like ulcerative colitis, Crohn's disease, and arthritis by using the body's own immune system to fight the diseases. @abivax #abivax  #inflammation #IBD #rheum <a href="http://abivax.com" rel="noopener nofollow" target="_blank">Abivax.com</a> <a href="http://empoweredpatientradio.com/novel-anti-inflammatory-therapeutic-agent-showing-promise-for-ulcerative-colitis-with-dr-hartmut-ehrlich-abivax-transcript" rel="noopener nofollow" target="_blank">Download the transcript here</a>

Novel Anti-Inflammatory Therapeutic Agent Showing Promise for Ulcerative Colitis with Dr. Hartmut Ehrlich Abivax

Dr. Hartmut Ehrlich, CEO of Abivax discusses the exciting new progress that this French biotechnology company has observed in clinical trials of their most advanced clinical drug candidate, ABX464.  Originally designed to treat HIV by reducing the viral reservoir, Abivax determined the molecule could also be a game-changing treatment in a variety of inflammatory conditions like ulcerative colitis, Crohn's disease and arthritis. #Abivax #ABVX #HIV #UlcerativeColitis #UC #inflammation #IBD Abivax.com

Dr. Hartmut Ehrlich, CEO of Abivax discusses the exciting new progress that this French biotechnology company has observed in clinical trials of their most advanced clinical drug candidate, ABX464.  Originally designed to treat HIV by reducing the viral reservoir, Abivax determined the molecule could also be a game-changing treatment in a variety of inflammatory conditions like ulcerative colitis, Crohn's disease and arthritis. #Abivax #ABVX #HIV #UlcerativeColitis #UC #inflammation #IBD <a href="http://abivax.com" rel="noopener nofollow" target="_blank">Abivax.com</a>

Drug Moves From Antiviral to Treating Inflammatory Diseases with Dr. Hartmut Ehrlich Abivax